Alcohol is the number one modifiable risk factor for dementia

huy-phan-587849-unsplash

Marie Crabbe looks at a recent retrospective cohort study in The Lancet Public Health which explores the contribution of alcohol use disorders to the burden of dementia in France.

[read the full story...]

Statins for dementia prevention: well-tolerated, but Cochrane highlight lack of evidence

14799938159_ad8a4fdd8a_k

Rosalyn Nelson summarises a recently updated Cochrane systematic review of statins for dementia prevention, which finds no evidence to support their use.

[read the full story...]

Cognitive tests for dementia: MMSE, Mini-Cog and ACE-R

7158418_2215ef4a6e_b

Akshay Nair explores the results of a systematic review of cognitive tests for dementia and mild cognitive impairment, which focuses on the MMSE, Mini-Cog, ACE-R and MoCA instruments. Along the way he explains how diagnostic tests work and how sensitivity and specificity are useful measures to get your head around.

[read the full story...]

Cerebrolysin is a promising treatment for vascular dementia, but more research is needed, according to new Cochrane review

Pig

Vascular dementia is the second most common type of dementia after Alzheimer’s disease. It’s caused by damage to the network of blood vessels supplying the brain. Some symptoms are similar to those associated with Alzheimer’s and stroke, but in particular people with vascular dementia often experience difficulty thinking quickly, concentrating and communicating, as well as [read the full story…]